Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in ANCA-associated vasculitis (ABAVAS)
2006-001859-35Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Mar 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) comparing Abatacept + methotrexate + steroids with Placebo + methotrexate + steroids (2 arms). Primary endpoints: Primary response to treatment and Relapse rate over 24 months. Started Mar 2007; status: terminated.
02
Drugs
abatacept
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2006-001859-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001859-35.